Apotex Announces Health Canada Approval for Aflivu™ (Aflibercept Biosimilar)
Toronto, ON – July 2, 2025 – Apotex Inc. is pleased to announce that Health Canada has granted approval for Aflivu™ (aflibercept), a biosimilar to Eylea® (aflibercept). This significant milestone marks the availability of a new, high-quality, and more accessible treatment option for Canadians living with certain retinal diseases.
Aflivu™ is indicated for the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), and neovascular (wet) myopia. These conditions can lead to significant vision loss and impact the quality of life for many individuals. The approval of Aflivu™ by Health Canada underscores Apotex’s commitment to expanding access to essential medicines and offering innovative healthcare solutions.
A key aspect of the Aflivu™ approval is its availability in two convenient formats: a pre-filled syringe and a vial. This dual availability provides healthcare professionals with greater flexibility in prescribing and administering the medication, catering to different clinical needs and patient preferences.
“We are incredibly proud to bring Aflivu™ to Canadian patients and their healthcare providers,” said [Insert Name and Title of Apotex Representative, e.g., Dr. Jeff Cohen, President of Apotex], at Apotex. “Our team has worked diligently to develop and ensure the quality and efficacy of this biosimilar, and we are confident that Aflivu™ will offer a valuable treatment option, contributing to improved patient outcomes and greater accessibility to essential therapies.”
Biosimilars are highly similar to their reference biologic products, demonstrating no clinically meaningful differences in terms of safety, purity, and potency. The rigorous scientific review process conducted by Health Canada ensures that biosimilars meet the same high standards of quality and effectiveness as the original biologic medicines.
The introduction of Aflivu™ is expected to enhance competition within the market, potentially leading to more affordable treatment options for patients and the healthcare system. Apotex remains dedicated to its mission of providing high-quality, affordable medicines to Canadians and is committed to supporting patients and healthcare professionals as Aflivu™ becomes available.
Further information regarding the availability and distribution of Aflivu™ will be communicated in due course.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats’ at 2025-07-02 14:44. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.